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Pyrophosphate is a potent inhibitor of medial vascular
calcification where its level is controlled by hydrolysis via a
tissue-nonspecific alkaline phosphatase (TNAP). We sought to
determine if increased TNAP activity could explain the
pyrophosphate deficiency and vascular calcification seen in
renal failure. TNAP activity increased twofold in intact aortas
and in aortic homogenates from rats made uremic by feeding
adenine or by 5/6 nephrectomy. Immunoblotting showed an
increase in protein abundance but there was no increase in
TNAP mRNA assessed by quantitative polymerase chain
reaction. Hydrolysis of pyrophosphate by rat aortic rings was
inhibited about half by the nonspecific alkaline phosphatase
inhibitor levamisole and was reduced about half in aortas
from mice lacking TNAP. Hydrolysis was increased in aortic
rings from uremic rats and all of this increase was inhibited
by levamisole. An increase in TNAP activity and
pyrophosphate hydrolysis also occurred when aortic rings
from normal rats were incubated with uremic rat plasma.
These results suggest that a circulating factor causes
pyrophosphate deficiency by regulating TNAP activity and
that vascular calcification in renal failure may result from the
action of this factor. If proven by future studies, this
mechanism will identify alkaline phosphatase as a potential
therapeutic target.
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Vascular disease is common in renal failure and is responsible
for much of the morbidity and mortality in end-stage renal
disease. One component of this that is receiving increased
attention is calcification of the arterial media, which is
distinct from the intimal calcification associated with
atherosclerosis. The extent and natural history of medial
calcification in end-stage renal disease is unknown because
atherosclerotic calcification is often present in these patients
as well and recent studies using electron-beam computed
tomography to quantitate coronary artery calcification have
not distinguished between these forms. However, these
studies do indicate that virtually all hemodialysis patients
eventually develop coronary artery calcification.1 A survey
almost 30 years ago, based on soft-tissue X-rays that probably
detect only medial calcification, found that 40% of patients
with chronic renal failure had calcification whether or not
they were undergoing dialysis.2 The true incidence was
probably higher due to the insensitivity of plain X-rays.
Clinical practice to prevent medial vascular calcification in
end-stage renal disease is based on the flawed assumption
that it is merely a manifestation of plasma concentrations of
Ca2þ and PO4
3 that are above the solubility product for
Ca3(PO4)2.
3 This clearly cannot be the entire explanation
since medial calcification is commonly seen in diabetes and
in aging, and in several genetic defects in the presence of
normal plasma calcium and phosphate concentrations.4–7
These observations suggest that calcification can occur at
normal concentrations of calcium and phosphate and that
mechanisms are normally in place to inhibit this. Thus,
vascular calcification must result from a failure of these
inhibitory mechanisms in addition to the disturbances in
mineral metabolism.
Pyrophosphate is a well-established inhibitor of calcifica-
tion in cartilage, of calcium oxalate crystallization in the
kidney,8,9 and of vascular calcification in vitamin D-toxic
rats.10 It is a direct and potent inhibitor of hydroxyapatite
formation in vitro, and even small concentrations in plasma
(2–4 mM) are sufficient to completely prevent crystallization
from saturated solutions of calcium and phosphate.8,9,11 We
have shown that pyrophosphate (PPi) is released by aortas in
culture and that calcification of these aortas in the presence of
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high phosphate and calcium concentrations only occurs when
the PPi is removed.12 Consistent with this, humans with low
levels of PPi due to the absence of the PPi-producing enzyme
PC1 develop severe, fatal arterial calcification.5,13
Tissue-nonspecific alkaline phosphatase (TNAP) is a key
determinant of tissue PPi levels and calcification.14 This
ectoenzyme hydrolyzes PPi and its absence in humans
(hypophosphatasia) increases plasma PPi concentrations15
and results in defective bone mineralization. This phenotype
is recreated in mice lacking TNAP16 and is corrected by
reducing PPi levels.17 Whether TNAP has a similar role in
vascular smooth muscle calcification is not known. We
recently showed that plasma PPi levels are reduced in
hemodialysis patients,18 suggesting that PPi deficiency might
contribute to uremic vascular calcification. To determine
whether there is an increase in TNAP that could explain PPi
deficiency and calcification in smooth muscle in renal failure,
we assayed alkaline phosphatase and the hydrolysis of PPi in
aortas from uremic rats and in normal aortas cultured under
uremic conditions.
RESULTS
The concentrations of urea, calcium, and phosphate in the
adenine-fed rats and control pair-fed rats are shown in
Table 1. The adenine-fed rats had ninefold higher urea levels
and 2.5-fold higher phosphate levels, and slightly higher
calcium levels. Alkaline phosphatase activity was 92% greater
in aortic extracts from adenine-fed rats than in that from
control rats (Figure 1). A similar increase (126%) was
observed in the remnant kidney model of uremia. The serum
urea concentration in these rats was 113±22 mg per 100 ml,
a little more than half the level in the adenine-fed rats. The
increase in alkaline phosphatase activity was even greater
(142%) when intact aortas (adenine-fed rats) were assayed.
To determine the mechanism by which renal failure increases
AP activity, protein and mRNA levels were examined.
Immunoblots of aortic extracts (Figure 2) revealed a
prominent band at approximately 75 kD that was absent in
bone from Akp2/ mice but not wild-type mice, confirm-
ing its identity as TNAP. Densitometry revealed a 126%
increase in signal from 52.5±9.2 U in six control aortas to
119±9.1 U in seven uremic aortas (Po0.001). Removal of
endothelium by swabbing the luminal surface did not reduce
AP activity (not shown), and adventitia was removed prior to
assay, indicating that vascular smooth muscle was responsible
for the AP activity measured in the aortas.
To confirm that the increase in alkaline phosphatase
activity resulted in increased hydrolysis of PPi, aortas were
incubated with 32PPi in culture medium. Hydrolysis of PPi
was linear for at least 4 h in both control and uremic aortas
(Figure 3a) and there was no hydrolysis of PPi in culture
medium without aortas (not shown). As shown in Figure 3b,
hydrolysis was 59% greater in aortas from the adenine-fed
rats and, again, a similar increase (76%) was seen in aortas
from uremic, remnant kidney rats. Assays were repeated with
levamisole, an inhibitor of alkaline phosphatase, to determine
whether the increase in PPi hydrolysis was due to the
increased TNAP activity (Figure 4). Levamisole produced a
dose-dependent inhibition of alkaline phosphatase with 80%
inhibition at 1 mM (Figure 4a). The residual activity most
likely represents incomplete inhibition of TNAP. This
concentration of levamisole reduced PPi hydrolysis by
Table 1 | Plasma chemistries in control and adenine-fed rats
Urea N
(mg per 100 ml)
Phosphate
(mg per 100 ml)
Calcium
(mg per 100 ml)
Control 22±1.9 4.0±0.5 8.2±0.2
Adenine-fed 202±6* 10.3±1.0* 9.16±0.2**
*Po0.001; **Po0.01.
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Figure 1 | Alkaline phosphatase activity in aortas from uremic (filled bars) and control pair-fed rats (open bars). (a) Hydrolysis of
p-nitrophenylphosphate in homogenates of aortas from adenine-fed rats, expressed as mg of protein. (b) Hydrolysis of p-nitrophenylphosphate
in homogenates of aortas from nephrectomized rats, expressed as mg protein. (c) Hydrolysis of p-nitrophenylphosphate by intact,
freshly isolated aortas from adenine-fed rats, expressed as mg dry weight. Results are the meansþ s.e. of the number of animals indicated
in parentheses. *Po0.0001; **Po0.002 vs control.
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41±9% in aortas from control pair-fed rats (Figure 4b).
The increased hydrolysis in uremic aortas was completely
inhibited by levamisole, with no increase in levamisole-
resistant hydrolysis, indicating that TNAP was responsible
for the increased hydrolysis of PPi. Hydrolysis of PPi by
smooth muscle TNAP was confirmed in Akp2/ mice,
which lack TNAP.16,19 Like patients with hypophophatasia,
these mice are characterized by hypophosphatasemia due to
global deficiency of TNAP activity, endogenous accumu-
lation of the AP substrates inorganic PPi and pyridoxal-
50-phosphate, and impaired skeletal matrix mineralization
leading to rickets or osteomalacia. Unfortunately, these mice
do not live for more than 2 weeks after birth, making the assay
technically difficult and prohibiting uremia from being
studied. Because of the limited amount of tissue available,
the assay was extended to 66 h and the results were
normalized to length of aorta rather than weight. As shown
in Figure 5, hydrolysis of PPi was linear over this time and was
substantially reduced in each of the homozygous mouse
aortas. The hydrolysis rate in aortas from homozygous mice
(0.068±0.005 pmol h1 mm1) was 44% the rate in wild-type
mice (0.156±0.007 pmol h1 mm1). The rate in hetero-
zygote aortas (0.136±0.004 pmol h1 mm1) was slightly
but not significantly lower than that in wild-type aortas.
105 kDa
Uremic aortas Control aortas
Mouse  
TNAP 
+/+
75 kDa
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Figure 2 | Immunoblot of extracts from control and uremic aortas
using a polyclonal antibody against TNAP. Also shown are bone
extracts from wild-type (TNAPþ /þ ) mice and mice lacking TNAP.
Each sample was 50mg of protein.
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Figure 3 | Hydrolysis of PPi by rat aorta. (a) Time course showing
representative results from a single uremic rat (5/6 nephrectomy)
and a control rat. (b) Hydrolysis rate in aortas from uremic (filled bars)
and control pair-fed rats (open bars). Results are the meansþ s.e.
of the number of animals indicated in parentheses. *Po0.0001;
**Po0.005 vs control.
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Figure 4 | Effect of levamisole on alkaline phosphatase and PPi
hydrolysis in intact rat aorta. (a) Alkaline phosphatase activity in
aortic rings from normal rats at different concentrations of
levamisole, expressed per mg dry weight. (b) Hydrolysis of PPi by
aortas from uremic and control pair-fed rats in the absence (black
bars) and presence (gray bars) of 1 mM levamisole. Results are the
meansþ s.e. of seven control and five uremic aortas.
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Quantitative PCR was performed to determine whether the
upregulation of TNAP was transcriptional and whether it was
related to osteogenic transformation in the smooth muscle. As
shown in Table 2, the quantity of TNAP mRNA was the same
in aortas from uremic (adenine-fed) and control rats. There
was also no difference in the abundance of mRNA for cbfa-1, a
transcription factor for osteogenesis, and bone gla protein, a
bone-specific protein. The amount of cbfa-1 mRNA was very
low and mRNA for bone gla protein was essentially
undetectable. In contrast, ROS 17/2.8 osteosarcoma cells
contained over 100-fold more mRNA for cbfa-1 and bone
gla protein. An increase in mRNA was detected for
osteopontin, which is also upregulated in uremic vessels
(K Lomashvili and WC O’Neill, unpublished data), demon-
strating the ability of quantitative PCR to detect increased gene
transcription in uremic aorta. The possibility that a circulating
factor or factors is responsible for the upregulation of alkaline
phosphatase was investigated by examining the effect of
uremic plasma on normal aortas maintained in culture
(Figure 6). We have previously demonstrated the viability of
these aortas for up to 2 weeks in serum-free medium.12 Under
these conditions, all the AP activity remains in the vessels with
none detected in the medium. Culture for 9 days in medium
containing 10% uremic, heat-inactivated rat plasma increased
AP activity in aortic extracts by 141% and increased PPi
hydrolysis in intact aortas by 57% compared to culture with
control plasma (Po0.001 for both).
DISCUSSION
This study demonstrates that renal failure increases the
expression in vascular smooth muscle of TNAP, a key enzyme
in the mineralization of bone and cartilage. The role of TNAP
in calcification was originally thought to be the provision of
inorganic phosphate from organic phosphates but recent data
have demonstrated that it functions instead to hydrolyze and
reduce the levels of extracellular pyrophosphate, an endo-
genous inhibitor of hydroxyapatite formation. Both mice and
humans lacking TNAP have increased PPi levels and
mineralization defects,16 and in mice, these can be corrected
by crossing them with mice deficient in extracellular PPi
production due to the absence of ectonucleotide pyropho-
sphorylase or the putative PPi transporter Ank.17 Further-
more, overexpression of TNAP can induce ectopic
calcification.14 Since PPi is also an important inhibitor of
vascular calcification, it is likely that TNAP plays a key role in
mineralization of vascular smooth muscle as well.
The increased hydrolysis of PPi resulting from upregula-
tion of TNAP in uremic rat aorta would be expected
to promote vascular calcification by lowering PPi
levels. Although it is not possible to measure extracellular
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Figure 5 | Hydrolysis of PPi in aortas from mice lacking tissue-
nonselective alkaline phosphatase (Akp2/ mice; solid circles),
from heterozygote mice (open circles), and wild-type mice
(triangles). Each line represents a single aorta.
Table 2 | Quantitation of mRNA in rat aorta and ROS cells
Copies per 106 18S RNA
mRNA Control aorta Uremic aorta ROS cells Fold increase in uremia P-value
Alkaline phosphatase 42±4 49±12 369 1.2 NS
cbfa-1 11±4 16±6 5900 1.5 NS
Bone gla protein o0.01 o0.01 128 1.4 NS
Osteopontin 420±90 2030±580 109 4.8 o0.05
NS, nonsignificant; ROS, rat osteosarcoma.
Control and uremic samples were run simultaneously for each comparison and the values are means±s.e.m. of five separate aortas. Data for the ROS cells are from a single
assay.
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Figure 6 | Effect of uremic plasma on cultured rat aortas. Aortic
rings were cultured for 9 days in 10% plasma from control (open bars) or
uremic (filled bars) rats. (a) Alkaline phosphatase activity in
homogenates expressed per mg protein. (b) Hydrolysis of PPi expressed
per dry weight. Results are the meansþ s.e. of the number of animals
indicated in parentheses. *Po0.0001; **Po0.005 vs control.
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PPi levels in aorta, we have demonstrated decreased plasma
levels in patients with end-stage renal disease undergoing
hemodialysis,18 which likely reflect a deficiency at the tissue
level. It is important to distinguish vascular TNAP from
circulating TNAP. The former is entirely tissue-bound,
consistent with the localization of this ectoenzyme on the
extracellular surface,20 while the latter likely derives from
apoptosis of osteoblasts20 and is an indication of bone turnover.
Although the circulating form is also enzymatically active, it is
unlikely to achieve the local effect of the membrane-bound
enzyme in the vessel wall. There is no correlation between
circulating levels of TNAP and PPi.18 Thus, it is unlikely that
circulating TNAP explains the apparent connection between
bone turnover and vascular calcification.
Levamisole, an inhibitor of TNAP, reduced PPi hydrolysis
in rat aorta, consistent with the ability of TNAP to hydrolyze
PPi in vitro.21 Despite the fact that 1 mM levamisole inhibited
TNAP activity (p-nitrophenyl phosphate hydrolysis) by 79%,
PPi hydrolysis was reduced by only 41%, indicating that
TNAP accounts for about half of the PPi hydrolysis in rat
aorta. This was confirmed by showing that PPi hydrolysis was
reduced only 56% in aortas from mice lacking TNAP
compared to aortas from wild-type mice. The identity of
the enzyme responsible for TNAP-independent hydrolysis is
not known but, since all of the increase in PPi hydrolysis in
uremic aortas was inhibited by levamisole, the other
enzyme(s) is not upregulated in uremia.
Because TNAP is an ectoenzyme, its regulation is
principally through changes in protein expression and,
consistent with this, the increase in TNAP activity (92%)
and protein (126%) in uremic aortas were similar. However,
this increase in TNAP protein did not appear to be
transcriptionally mediated since the quantity of TNAP
mRNA did not increase in uremic aortas. Because of the
insensitivity of quantitative PCR to small changes in mRNA,
a small increase in mRNA resulting in a doubling of TNAP
protein cannot be ruled out. A similar mRNA-independent
upregulation of TNAP occurs in L cells in response to
elevations in cyclic AMP,22 indicating that TNAP can be
regulated through changes in protein degradation or
translation efficiency. The fact that the increase was also
observed in the remnant model of renal failure indicates that
it was related to uremia and not due to some other effect of
adenine. The increase observed in aortas cultured with
uremic plasma indicates that a circulating factor is involved.
Candidates include hyperphosphatemia and elevated levels of
parathyroid hormone, which we have previously shown to
upregulate AP activity in normal aortas in culture.23
Although hyperphosphatemia could contribute to the
upregulation of AP in vivo, the 10-fold dilution of plasma
in culture would result in an insignificant increase in the
in vitro studies. The plasma dilution would have also
minimized any effect of PTH but this cannot be ruled out.
Tissue-nonspecific alkaline phosphatase is an important
component of osteoblastic differentiation, and transforma-
tion of vascular smooth muscle cells into osteoblastic cells has
been proposed as a mechanism for medial calcification.24
However, there was no evidence of osteogenesis, as indicated by
lack of induction of cbfa-1 or bone Gla protein, in aortas from
uremic, adenine-fed rats. These results indicate that the increase
in AP activity in uremic vessels is not due to osteoblastic
transformation and that, in this model, uremia does not
produce osteoblastic transformation in vascular smooth muscle.
The results of this study suggest that preventing
upregulation of TNAP or inhibiting its hydrolysis of PPi
could reduce uremic vascular calcification. Unfortunately,
tools to answer this hypothesis do not currently exist. The
Akp2 mice that lack TNAP should be protected from uremic
vascular calcification but survive for only 2 weeks after birth,
preventing uremia from being tested. Levamisole is a weak
inhibitor of TNAP and has other effects in vivo,25 and the
levels necessary to inhibit TNAP are not achievable in vivo.
The development of more potent and specific inhibitors26
may enable TNAP to be a therapeutic target in the future.
MATERIALS AND METHODS
Uremic rats
Chronic renal failure was produced by feeding adenine to rats.27,28
This results in crystallization of 2,8-dihydroxyadenine in the tubules
and interstitium with resulting renal fibrosis and atrophy and all the
metabolic abnormalities of chronic renal failure.27 Rats were fed
standard rat chow (0.95% calcium and 0.4% phosphorus)þ 0.75%
adenine for 4 weeks, after which blood was collected and aortas were
harvested. Aortic calcification does not occur with this diet. Control
rats were fed a restricted diet of normal rat chow so that their weight
loss matched with that of the adenine-fed rats. Except where
indicated, all studies were performed on aortas from adenine-fed
rats. In some studies, renal failure was produced by unilateral
nephrectomy followed by partial infarction of the remnant kidney
and a high-protein diet as previously described.29
Aortic culture
Aortic culture was performed as previously described.12 Briefly,
aortas were removed under sterile conditions from male Sprague–-
Dawley rats weighing 150–250 g and adventitia was carefully
removed. Adventitia was not completely removed as this led to
smooth muscle injury. The vessels were cut into 3–4 mm rings and
placed in Dulbecco’s modified Eagle’s medium (Mediatech,
Herndon, VA, USA) without serum at 371C in a 5% CO2 incubator
with medium changes every 3 days. The concentrations of calcium
and phosphate in this medium are 1.8 and 0.9 mM respectively.
Alkaline phosphatase activity
Alkaline phosphatase was measured colorimetrically as the hydro-
lysis of p-nitrophenyl phosphate at pH 10.5 according to instruc-
tions from the supplier (Sigma Diagnostics, St Louis, MO, USA).
Aortas were homogenized in radioimmunoprecipitation assay
buffer (10 mM Tris, pH 7.4; 2.5 mM EDTA; 50 mM NaF; 1 mM
Na4P2O7.10H2O; 1% Triton X-100; 10% glycerol; 1% deoxycholate,
1 mg ml1 aprotinin, 0.18 mg ml1 phenylmethanesulphonylfluoride,
0.18 mg ml1 orthovanadate, 1% Triton X-100 in 0.9% saline) on ice
and centrifuged in a microfuge at the maximum speed for 5 min.
Supernatant was removed for assay. Assays in intact aortas were
performed in Hanks buffered salt solution (pH 7.4) containing 1 mM
Ca and 4 mg ml1 p-nitrophenyl phosphate.
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Alkaline phosphatase protein and mRNA
Immunoblots were performed on aortic extracts prepared as above
and separated by sodium dodecyl sulfate polyacrylamide gel
electrophoresis. Following transfer to polyvinylidene difluoride
membranes, the blots were developed using a polyclonal antibody
developed against rat liver alkaline phosphatase30 and kindly
provided by Dr Y Ikehara. Total RNA was isolated from rat aortas
using a phenol extraction method (ToTALLY RNA total RNA
Isolation kit; Ambion, Austin, TX, USA). Integrity of RNA was
assessed by agarose gel electrophoresis. cDNA was synthesized from
RNA by reverse transcriptase primed with oligo(dT)20 using
Thermoscript RT-PCR (Invitrogen, Carlsbad, CA, USA). For 18S
RNA, the specific primer GAGCTGGAATTACCGCGGCT was used
for reverse transcription.31 Quantitative polymerase chain reaction
was performed on cDNA samples with an iCycler iQ Real Time PCR
detection system using iQ SYBR GREEN SUPERMIX (Biorad,
Hercules, CA, USA). Primers for TNAP were TGGACGGTGAACGG
GAGAAC (forward) and TGAAGCAGGTGAGCCATAGG (reverse).
These primers span one intron and include neighboring exons.
Primers for 18S RNA were GGGAGGTAGTGACGAAAAATAACAAT
(forward) and TTGCCCTCCAATGGATCCT (reverse) as previously
described.31 Melting curves revealed only single peaks. Serial
dilutions of TNAP and 18S cDNA were used to construct standard
curves for quantitative polymerase chain reaction and to calculate
amplification efficiencies. Nearly full-length cDNA for TNAP was
cloned from rat osteosarcoma cell cDNA using pCRII-TOPO
(Invitrogen). ROS 17/2.8 cells were kindly provided by Dr Mark Nanes.
Pyrophosphate hydrolysis
Aortic rings were preincubated in Dulbecco’s modified Eagle’s
medium for 1 h at 371C in a 5% CO2 incubator, after which the
medium was changed to Dulbecco’s modified Eagle’s medium
containing 1 mM sodium pyrophosphate and [32P]PPi (mCi ml1).
Levamisole was added from a stock solution of 100 mM in 25%
dimethylsulfoxide to a final concentration of 1 mM. Samples of
medium (20 ml) were mixed with 800ml of ammonium molybdate
(to bind orthophosphate) in 0.75 M sulfuric acid. The samples were
then extracted with 1.6 ml of isobutanol/petroleum ether (4:1) to
separate phosphomolybdate from PPi, and 400 ml of the top
(organic) phase containing phosphomolybdate was removed for
counting of radioactivity. The rings were then dried and weighed.
Mice lacking tissue-nonspecific alkaline phosphatase
The generation and characterization of Akp2/ mice, deficient in
TNAP, has been reported previously.16,19 Akp2/ mice (C57BL/6
and 129J hybrid background) were maintained by heterozygote
breeding. All animals (breeders, nursing moms, pups) had free
access to a modified laboratory rodent diet 5001 with 325 p.p.m.
pyridoxine (No. 48057, TestDiet), since supplementation with
vitamin B6 extends the life of the Akp2/ pups for a few days.
Akp2/ pups were killed at day 16 for isolation of the aortas.
Statistics
Data are presented as means±s.e.m. Significance was tested by
two-tailed Student’s t-test. For multiple comparisons, the P-value
was multiplied by the number of comparisons. For skewed data, a
logarithmic transformation was applied prior to statistical analysis.
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